Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness

Gelfand, Erwin W.; Cui, Zhi Hua; Takeda, Katsuyuki; Kanehiro, Arihiko; Joetham, Anthony

doi:10.1016/s0091-6749(03)01882-7

Cited by 19 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that fexofenadine reduced the severity of itching of contact dermatitis for 72 h throughout the treatment period suggests that fexofenadine might inhibit itching that is due to delayed‐type hypersensitivity, even if immediate‐type and subsequent late responses occur in the contact dermatitis induced by DPCP as they do in mice. Recently, it has been reported that fexofenadine inhibits many inflammatory mediators: Th2 chemokine production by cultured keratinocytes 10 and peripheral blood cells, 11 in vitro and in vivo intercellular adhesion molecule (ICAM)‐1 synthesis by conjunctival and nasal epithelial cells, 12 IL‐8 and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) from isolated nasal epithelial cells, 13 IgE mediated histamine‐ and IL‐4‐release from human basophils, 14 and T‐cell function of mice in vivo 15 . Some of these anti‐inflammatory effects, in combination with strong antihistaminergic effects, might reduce the severity of itching in contact dermatitis.…”

Section: Discussionmentioning

confidence: 99%

Fexofenadine, an H1‐receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata

Katagiri

Arakawa

Hatano

et al. 2006

The Journal of Dermatology

View full text Add to dashboard Cite

Antihistamines have been used for the treatment of not only allergic diseases such as allergic urticaria and rhinitis, but also of eczematous skin diseases because of their anti-pruritic effects. Moreover, the pruritus associated with eczematous diseases is considered to be induced, in part, by histamine. However, it is unclear whether antihistamines inhibit the itch of eczematous diseases in the absence of topical corticosteroids. In this study, we investigated the anti-pruritic effect of the antihistamine, fexofenadine, on the itch of contact dermatitis that was induced by topical application of diphenylcyclopropenone for the treatment for alopecia areata. Thirteen patients with alopecia areata, who had been treated weekly with topical immunotherapy with diphenylcyclopropenone for 3 months to 2 years, recorded the severity of their itching on a visual analog scale before and 3, 6, 12, 24, 48 and 72 h after application of diphenylcyclopropenone for 4 consecutive weeks. Seven patients took fexofenadine during the first and third weeks, and six patients took fexofenadine during the second and fourth weeks. The severity of itching reached a maximum 6-12 h after the induction of the contact dermatitis in most of the patients. However, fexofenadine partially but rapidly reduced the severity of itching for 72 h during the entire period of treatment in the absence of topical corticosteroids. Our results suggest that fexofenadine can be beneficial in the daily management of patients with itching due to eczematous disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Fexofenadine, an H1‐receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata

Katagiri

Arakawa

Hatano

et al. 2006

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Allergen challenge studies have shown that exposure to an allergen to which an asthmatic has been sensitized is likely to bring about an asthma exacerbation [41][42][43]. Conversely, avoidance of such allergens may lead to resolution of the exacerbation.…”

Section: Environmental Controlmentioning

confidence: 99%

Asthma in Children and Adolescents: A Comprehensive Approach to Diagnosis and Management

Chang

2011

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Asthma is a chronic disease that has a significant impact on quality of life and is particularly important in children and adolescents, in part due to the higher incidence of allergies in children. The incidence of asthma has increased dramatically during this time period, with the highest increases in the urban areas of developed countries. It seems that the incidence in developing countries may follow this trend as well. While our knowledge of the pathophysiology of asthma and the available of newer, safer medication have both improved, the mortality of the disease has undergone an overall increase in the past 30 years. Asthma treatment goals in children include decreasing mortality and improving quality of life. Specific treatment goals include but are not limited to decreasing inflammation, improving lung function, decreasing clinical symptoms, reducing hospital stays and emergency department visits, reducing work or school absences, and reducing the need for rescue medications. Non-pharmacological management strategies include allergen avoidance, environmental evaluation for allergens and irritants, patient education, allergy testing, regular monitoring of lung function, and the use of asthma management plans, asthma control tests, peak flow meters, and asthma diaries. Achieving asthma treatment goals reduces direct and indirect costs of asthma and is economically cost-effective. Treatment in children presents unique challenges in diagnosis and management. Challenges in diagnosis include consideration of other diseases such as viral respiratory illnesses or vocal cord dysfunction. Challenges in management include evaluation of the child's ability to use inhalers and peak flow meters and the management of exercise-induced asthma.

show abstract

“…Fexofenadine (FFD) is an already discovered antihistamine drug with a highly selective HI receptor blocker and is commonly used in many allergic diseases, such as chronic idiopathic urticaria and rhinallergosis ( Finn et al, 1999 ; Gelfand et al, 2003 ; Leurs et al, 2011 ). Among them, FFD can suppress eosinophilia and systemic anaphylaxis, and block the release of the inflammatory cytokines induced by the H1R/p38 and NF-κB pathway by blocking HI receptors ( Watanabe et al, 2004 ; Park et al, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Fexofenadine Protects Against Intervertebral Disc Degeneration Through TNF Signaling

Liu

Wei

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Objective: Fexofenadine (FFD) is an antihistamine drug with an anti-inflammatory effect. The intervertebral disc (IVD) degeneration process is involved in inflammation in which tumor necrosis factor-α (TNF-α) plays an important role. This study aims to investigate the role of FFD in the pathological process of IVD degeneration.Methods: Safranin O staining was used for the measurement of cartilageous tissue in the disc. Hematoxylin-Eosin (H&E) staining was used to determine the disc construction. A rat needle puncture model was taken advantage of to examine the role of FFD in disc degeneration in vivo. Western Blotting assay, immunochemistry, and immunoflurence staining were used for the determination of inflammatory molecules. ELISA assay was performed to detect the release of inflammatory cytokines. A real-time PCR assay was analyzed to determine the transcriptional expressions of molecules.Results: Elevated TNF-α resulted in inflammatory disc degeneration, while FFD protected against TNF-α-induced IVD degeneration. Mechanism study found FFD exhibited a disc protective effect through at least two pathways. (a) FFD inhibited TNF-α-mediated extracellular matrix (ECM) degradation and (b) FFD rescued TNF-α induced inflammation in disc degeneration. Furthermore, the present study found that FFD suppressed TNF-α mediated disc degeneration via the cPLA2/NF-κB signaling pathway.Conclusions: FFD provided another alternative for treating disc degeneration through a novel mechanism. Additionally, FFD may also be a potential target for the treatment of other inflammatory-related diseases, including IVD degeneration.

show abstract

Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness

Cited by 19 publications

References 16 publications

Fexofenadine, an H1‐receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata

Fexofenadine, an H1‐receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata

Asthma in Children and Adolescents: A Comprehensive Approach to Diagnosis and Management

Fexofenadine Protects Against Intervertebral Disc Degeneration Through TNF Signaling

Contact Info

Product

Resources

About